{"id":"NCT00650546","sponsor":"Indiana University","briefTitle":"Role of Exenatide in NASH-a Pilot Study","officialTitle":"Role of Exenatide in Treatment of NASH-a Pilot Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-08","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2008-04-01","resultsPosted":"2016-05-12","lastUpdate":"2017-04-11"},"enrollment":8,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Nonalcoholic Fatty Liver Disease"],"interventions":[{"type":"DRUG","name":"Exenatide","otherNames":["Byetta"]}],"arms":[{"label":"A pre treatment NAS score","type":"EXPERIMENTAL"}],"summary":"We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.","primaryOutcome":{"measure":"Number of Patients With Improvement in Liver Histology After Treatment With Exenatide","timeFrame":"between baseline and 24-28 weeks after initiating treatment","effectByArm":[{"arm":"Treatment With Exenatide","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["16012941","15017611","12843147","14752837","15017657","14512888","1700785","1313797","9020121","10027577","21131943"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["abdominal pain along with nausea"]}}